沙利度胺与柳氮磺胺吡啶联合应用对大鼠实验性诱导炎性肠病的影响。

Effect of combination of thalidomide and sulfasalazine in experimentally induced inflammatory bowel disease in rats.

作者信息

Prakash O, Medhi B, Saikia U N, Pandhi P

机构信息

Department of Pharmacology and Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India

出版信息

Indian J Exp Biol. 2011 Sep;49(9):672-8.

PMID:21941940

Abstract

Thalidomide provided significant protection against tri nitro benzene sulfonic acid induced colitis. Combination therapy also reduced colonic inflammation and all the biochemical parameters (myeloperoxidase assay, malondialdehyde assay and tumor necrosis factor-alpha, estimation) were significant as compared to control as well as thalidomide alone treated group. Combination therapy showed additive effect of thalidomide which restored lipid peroxidation as well as reduced myeloperoxidase and TNF-a towards the normal levels. Morphological and histological scores were significantly reduced in combination groups. In experimental model of colitis, oral administration of thalidomide (150 mg/kg) alone as well as its combination with sulfasalazine (360 mg/kg) significantly reduced the colonic inflammation. The results indicate the additive effect of thalidomide with sulfasalazine in rat colitis model which requires further confirmation in human studies.

摘要

沙利度胺对三硝基苯磺酸诱导的结肠炎具有显著的保护作用。联合治疗也减轻了结肠炎症，与对照组以及单独使用沙利度胺治疗的组相比，所有生化参数（髓过氧化物酶测定、丙二醛测定和肿瘤坏死因子-α 测定）均有显著差异。联合治疗显示出沙利度胺的相加作用，它恢复了脂质过氧化，并使髓过氧化物酶和肿瘤坏死因子-α 降至正常水平。联合治疗组的形态学和组织学评分显著降低。在结肠炎实验模型中，单独口服沙利度胺（150 mg/kg）及其与柳氮磺胺吡啶（360 mg/kg）联合使用均显著减轻了结肠炎症。结果表明沙利度胺与柳氮磺胺吡啶在大鼠结肠炎模型中具有相加作用，这需要在人体研究中进一步证实。